Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption

被引：24
|
作者：
Laroni, A. [1 ]
Brogi, D. [1 ]
Milesi, V. [1 ]
Abate, L. [1 ]
Uccelli, A. [1 ]
Mancardi, G. L. [1 ]
机构：
[1] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, I-16132 Genoa, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2013年 / 19卷 / 09期
关键词：
MULTIPLE-SCLEROSIS;
D O I：
10.1177/1352458512468498
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1236 / 1237
页数：2
相关论文
共 50 条
  • [1] Early Initiation of Fingolimod Treatment Reduces the Recurrence of Disease Activity after Natalizumab Discontinuation in Multiple Sclerosis
    Havla, Joachim
    Tackenberg, Bjorn
    Hellwig, Kerstin
    Krumbholz, Markus
    Meinl, Ingrid
    Seitz, Florian
    Eienbroecker, Christian
    Gold, Ralf
    Hohlfeld, Reinhard
    Kleiter, Ingo
    Kuempfel, Tania
    NEUROLOGY, 2013, 80
  • [2] Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis
    Joachim Havla
    Björn Tackenberg
    Kerstin Hellwig
    Ingrid Meinl
    Markus Krumbholz
    Florian Seitz
    Christian Eienbröker
    Ralf Gold
    Reinhard Hohlfeld
    Ingo Kleiter
    Tania Kümpfel
    Journal of Neurology, 2013, 260 : 1382 - 1387
  • [3] Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis
    Havla, Joachim
    Tackenberg, Bjoern
    Hellwig, Kerstin
    Meinl, Ingrid
    Krumbholz, Markus
    Seitz, Florian
    Eienbroeker, Christian
    Gold, Ralf
    Hohlfeld, Reinhard
    Kleiter, Ingo
    Kuempfel, Tania
    JOURNAL OF NEUROLOGY, 2013, 260 (05) : 1382 - 1387
  • [4] Fingolimod reduces the risk of recurrence of disease activity during the first 12 months after natalizumab discontinuation in multiple sclerosis
    Havla, J.
    Tackenberg, B.
    Hellwig, K.
    Meinl, I.
    Krumbholz, M.
    Seitz, F.
    Eienbroecker, C.
    Gold, R.
    Hohlfeld, R.
    Kleiter, I.
    Kuempfel, T.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 230 - 231
  • [5] Reduced risk of relapses in the switch between natalizumab and fingolimod in 91 patients
    Fragoso, Y. D.
    Adoni, T.
    Alves-Leon, S. V.
    Apostolos-Pereira, S. L.
    Araujo, Y. R.
    Becker, J.
    Brooks, J. B.
    Correa, E. C.
    Damasceno, A.
    Damasceno, C. A.
    Ferreira, M. L.
    Gama, P. D.
    Gama, R. A.
    Gomes, S.
    Goncalves, M. V.
    Grzesiuk, A. K.
    Machado, S. C.
    Matta, A. P.
    Mendes, M. F.
    Ribeiro, T. A.
    Rocha, C. F.
    Ruocco, H. H.
    Sato, H.
    Simm, R. F.
    Tauil, C. B.
    Vasconcelos, C. C.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 578 - 579
  • [6] Fingolimod after natalizumab and the risk of short-term relapse
    Jokubaitis, Vilija G.
    Li, Vivien
    Kalincik, Tomas
    Izquierdo, Guillermo
    Hodgkinson, Suzanne
    Alroughani, Raed
    Lechner-Scott, Jeannette
    Lugaresi, Alessandra
    Duquette, Pierre
    Girard, Marc
    Barnett, Michael
    Grand'Maison, Francois
    Trojano, Maria
    Slee, Mark
    Giuliani, Giorgio
    Shaw, Cameron
    Boz, Cavit
    Spitaleri, Daniele L. A.
    Verheul, Freek
    Haartsen, Jodi
    Liew, Danny
    Butzkueven, Helmut
    NEUROLOGY, 2014, 82 (14) : 1204 - 1211
  • [7] Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis
    Zhu, Chao
    Zhou, Zhen
    Roos, Izanne
    Merlo, Daniel
    Kalincik, Tomas
    Ozakbas, Serkan
    Skibina, Olga
    Kuhle, Jens
    Hodgkinson, Suzanne
    Boz, Cavit
    Alroughani, Raed
    Lechner-Scott, Jeannette
    Barnett, Michael
    Izquierdo, Guillermo
    Prat, Alexandre
    Horakova, Dana
    Havrdova, Eva Kubala
    Macdonell, Richard
    Patti, Francesco
    Khoury, Samia Joseph
    Slee, Mark
    Karabudak, Rana
    Onofrj, Marco
    Van Pesch, Vincent
    Prevost, Julie
    Monif, Mastura
    Jokubaitis, Vilija
    van der Walt, Anneke
    Butzkueven, Helmut
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (12): : 1330 - 1337
  • [8] Can fingolimod treatment influence disease progression after natalizumab discontinuation?
    Messina, M. J.
    Rodegher, M.
    Baroncini, D.
    Rocca, M. A.
    Filippi, M.
    Maida, S.
    Radaelli, M.
    Copetti, M.
    Martinelli, V.
    Ghezzi, A.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 268 - 269
  • [9] Recurrence of disease activity after repeated Natalizumab withdrawals
    Laura Ferrè
    Lucia Moiola
    Francesca Sangalli
    Marta Radaelli
    Valeria Barcella
    Giancarlo Comi
    Vittorio Martinelli
    Neurological Sciences, 2015, 36 : 465 - 467
  • [10] Recurrence of disease activity after repeated Natalizumab withdrawals
    Ferre, Laura
    Moiola, Lucia
    Sangalli, Francesca
    Radaelli, Marta
    Barcella, Valeria
    Comi, Giancarlo
    Martinelli, Vittorio
    NEUROLOGICAL SCIENCES, 2015, 36 (03) : 465 - 467
12345